Autoimmune Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Instruments, Reagents, Consumables), By Test Type (Routine Laboratory Tests, Inflammatory Markers, Antibodies & Immunologic Tests, Others), By Disease Type (Systemic Autoimmune Disease Diagnostics (Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Others), Localized Autoimmune Disease Diagnostics (Multiple Sclerosis, Type 1 Diabetes, Hashimoto’s Thyroiditis, Others)), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Region and Competition, 2020-2030F

Market Overview

Global Autoimmune Disease Diagnostics Market was valued at USD 5.74 billion in 2024 and is expected to reach USD 9.64 billion by 2030 with a CAGR of 9.03% during the forecast period. The Global Autoimmune Disease Diagnostics Market refers to the worldwide industry focused on the diagnosis and testing of autoimmune diseases. Autoimmune diseases are a group of disorders in which the immune system mistakenly attacks the body's own healthy tissues, leading to various health problems. The market for autoimmune disease diagnostics encompasses a wide range of products, services, and technologies aimed at identifying and monitoring these conditions. Autoimmune diseases are a group of more than 100 chronic, debilitating conditions that affect approximately 3% of the US population, or about 10 million people. Some of the most common autoimmune diseases include obesity, cardiovascular diseases, type 2 diabetes mellitus, and all cancers. 

Key Market Drivers

Rising Prevalence of Autoimmune Diseases

Autoimmune diseases have become a growing global health concern, affecting millions of people worldwide. These conditions occur when the body's immune system mistakenly targets its own tissues, leading to chronic inflammation and a wide range of health issues. As the prevalence of autoimmune diseases continues to rise, the Global Autoimmune Disease Diagnostics Market is experiencing significant growth. Autoimmune diseases are no longer considered rare. They have reached epidemic proportions, with millions of people across the globe suffering from various autoimmune conditions. Common autoimmune diseases include rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, and type 1 diabetes. The sheer volume of patients seeking diagnosis and treatment has boosted the demand for autoimmune disease diagnostics. Early diagnosis is crucial for managing autoimmune diseases effectively. Many of these conditions exhibit subtle symptoms in their early stages, making accurate and timely diagnosis challenging. However, as awareness about autoimmune diseases increases, individuals are more likely to seek medical attention when experiencing symptoms, driving the need for diagnostic tests that can confirm or rule out these conditions.

Moreover, the rising prevalence of autoimmune diseases has coincided with significant technological advancements in healthcare. Diagnostic tools and techniques have evolved rapidly, providing healthcare professionals with more accurate and efficient ways to detect autoimmune diseases. These advancements include serology tests, genetic testing, imaging modalities, and biomarker-based assays. Such innovations enhance the diagnostic capabilities and contribute to early intervention. The growth of the autoimmune disease diagnostics market is also linked to the trend of personalized medicine. Tailoring treatments based on an individual's unique genetic and immunological profile is gaining prominence. To prescribe personalized therapies effectively, precise diagnostics are required to identify the specific autoimmune disease and its severity, enabling clinicians to choose the most suitable treatment options. For instance, a study published in the American Journal of Managed Care (AJMC) in May 2021 reported an estimated prevalence of 276 cases per million adults for scleroderma in the U.S. A recent study found that autoimmune disorders now affect about one in ten individuals, with 80-100 known autoimmune diseases affecting more than 14 million Americans.

Technological Advancements

Technological advancements are reshaping the landscape of healthcare, and nowhere is this more evident than in the realm of autoimmune disease diagnostics. The Global Autoimmune Disease Diagnostics Market is experiencing remarkable growth, largely driven by innovations in diagnostic technologies. These advancements have not only improved the accuracy and efficiency of autoimmune disease diagnosis but have also expanded the market's reach and potential. Technological breakthroughs have led to the development of highly accurate and sensitive diagnostic tests for autoimmune diseases. Traditional diagnostic methods have been complemented by advanced serology tests, biomarker-based assays, genetic testing, and imaging techniques. These cutting-edge tools enable healthcare professionals to detect autoimmune diseases earlier and with greater precision, improving patient outcomes. Early diagnosis is crucial in autoimmune diseases, as timely intervention can slow disease progression and minimize complications. Technological advancements have enabled the detection of autoimmune diseases in their earliest stages, even before noticeable symptoms appear. This capability empowers healthcare providers to initiate appropriate treatment strategies promptly, leading to improved patient quality of life. The concept of personalized medicine is gaining traction in autoimmune disease diagnostics. Advancements in genetic testing and molecular profiling allow for a more precise understanding of an individual's immune system and genetic predisposition to autoimmune diseases. This information guides clinicians in tailoring treatment plans to suit each patient's unique profile, optimizing therapeutic outcomes. Technological innovations have enabled high-throughput screening, which allows for the rapid analysis of numerous samples simultaneously. This capability is particularly valuable in autoimmune disease diagnostics, where large-scale screening can help identify at-risk individuals and streamline diagnostic processes in clinical settings.

Expanding Product Portfolio

The Global Autoimmune Disease Diagnostics Market is on a growth trajectory, and one of the key factors propelling this expansion is the continuous expansion of product portfolios by diagnostic companies. As the prevalence of autoimmune diseases rises and the demand for accurate, early diagnosis increases, companies are investing in research and development to offer a broader range of innovative diagnostic solutions. Autoimmune diseases encompass a wide spectrum of conditions, each with its own unique characteristics and diagnostic challenges. An expanding product portfolio allows diagnostic companies to address this diversity effectively. By developing a variety of tests, biomarker panels, and imaging technologies, these companies can cater to the specific needs of different autoimmune diseases. The development of new diagnostic tools and assays has led to improved accuracy and specificity in autoimmune disease diagnostics. Advanced serology tests, genetic profiling, and biomarker-based assays provide healthcare professionals with more reliable and precise diagnostic results. These innovations reduce the chances of misdiagnosis and facilitate early intervention. The expansion of product portfolios includes the creation of point-of-care testing (POCT) devices. These compact and user-friendly diagnostic tools enable rapid testing at or near the patient's location, providing quick results and reducing the time required for diagnosis. POCT devices are especially valuable for autoimmune disease diagnostics as they allow for immediate treatment decisions. Continuous research and development efforts have led to the identification of novel biomarkers associated with autoimmune diseases. Diagnostic companies are incorporating these biomarkers into their product offerings, enhancing diagnostic accuracy and providing clinicians with valuable information for treatment decisions.

Geographical Expansion

The Global Autoimmune Disease Diagnostics Market is experiencing significant growth, and one of the pivotal factors propelling this expansion is geographical expansion. Diagnostic companies are extending their reach beyond traditional markets, tapping into emerging economies and regions where autoimmune diseases are increasingly prevalent. Geographical expansion allows diagnostic companies to access new markets and untapped patient populations. Emerging economies are witnessing a rising incidence of autoimmune diseases as lifestyle factors and healthcare awareness evolve. By entering these markets, diagnostic companies can meet the growing demand for autoimmune disease diagnostics and establish a strong presence. Expanding geographically often involves raising disease awareness in previously underserved regions. Diagnostic companies collaborate with local healthcare organizations and authorities to educate communities about autoimmune diseases. This increased awareness prompts individuals to seek timely diagnosis and treatment, contributing to market growth. Geographical expansion frequently goes hand-in-hand with investments in healthcare infrastructure. Diagnostic companies and healthcare providers collaborate to improve facilities, access to medical professionals, and diagnostic capabilities in these regions. This infrastructure development not only supports the growth of autoimmune disease diagnostics but also benefits overall public health. Different geographical regions may exhibit variations in the prevalence and types of autoimmune diseases. Expanding into diverse markets allows diagnostic companies to tailor their product portfolios to address region-specific needs. This customization ensures that the diagnostic tools offered are relevant and effective for the local population.

Download Free Sample Report

Key Market Challenges

Complexity of Autoimmune Diseases

One of the fundamental challenges in autoimmune disease diagnostics is the sheer complexity of these conditions. Autoimmune diseases can present with a wide array of symptoms, and their underlying mechanisms are often intricate and multifaceted. This complexity makes it challenging to develop diagnostic tests that are both accurate and comprehensive.

Lack of Specific Biomarkers

Many autoimmune diseases lack specific biomarkers that can be easily detected in diagnostic tests. While researchers have made significant strides in identifying relevant biomarkers, the absence of universally accepted markers for certain autoimmune diseases hampers the development of precise diagnostic tools.

High Diagnostic Costs

Diagnostic tests for autoimmune diseases can be costly, particularly when multiple tests are required for a definitive diagnosis. High diagnostic costs can deter patients from seeking testing, leading to delayed diagnosis and treatment. Additionally, these costs can strain healthcare systems and limit access to diagnostics, particularly in resource-constrained settings.

Variability in Disease Presentation

Autoimmune diseases can present differently in individuals, making diagnosis challenging. Symptoms may be vague or mimic other conditions, leading to misdiagnosis or delayed diagnosis. Variability in disease presentation requires healthcare professionals to maintain a high level of suspicion and consider a broad range of diagnostic possibilities.

Key Market Trends

Advances in Biomarker Discovery

Biomarkers play a crucial role in autoimmune disease diagnostics. Ongoing research is leading to the discovery of novel biomarkers that can improve diagnostic accuracy. These biomarkers are expected to become integral in identifying autoimmune diseases at earlier stages and monitoring disease progression more effectively.

Point-of-Care Testing (POCT)

Point-of-care testing is gaining prominence in autoimmune disease diagnostics. Miniaturized diagnostic devices and rapid testing kits allow for quick and convenient diagnosis at or near the patient's location. This trend not only reduces the time required for diagnosis but also enhances accessibility, especially in remote or underserved areas.

Telemedicine and Remote Monitoring

Telemedicine and remote monitoring technologies are becoming more integrated into autoimmune disease diagnostics. These approaches allow patients to consult with healthcare providers, receive diagnostic results, and manage their conditions from the comfort of their homes. This trend enhances patient engagement and access to specialized care.

Multiplex Testing

Multiplex testing involves the simultaneous analysis of multiple biomarkers or disease-related factors in a single diagnostic test. This trend is gaining traction in autoimmune disease diagnostics, enabling a more comprehensive assessment of a patient's condition. Multiplex tests can identify multiple autoimmune diseases in a single screening, leading to more efficient diagnosis.

Segmental Insights

End User Insights

Based on End User, the hospitals & clinics segment has emerged as a dominant player due to their pivotal role in healthcare infrastructure. These healthcare facilities serve as primary points of care for patients seeking diagnosis and treatment. With the increasing prevalence of autoimmune diseases and the need for accurate and timely diagnostics, hospitals and clinics become central hubs for autoimmune disease testing. They offer a wide range of diagnostic services, access to specialized medical professionals, and state-of-the-art equipment necessary for comprehensive autoimmune disease diagnosis. Moreover, the trend toward collaborative and multidisciplinary approaches to healthcare further solidifies the position of hospitals and clinics as key players in the autoimmune disease diagnostics market, as they provide integrated care and access to a wide array of diagnostic tools, including advanced imaging, genetic testing, and biomarker-based assays, essential for accurate diagnosis and effective disease management.

Download Free Sample Report

Regional Insights

Based on Region, North America hold the largest market share in 2024, primarily attributable to the implementation of the Affordable Care Act, the existence of supportive regulatory frameworks, and the proactive efforts led by the AARDA. Additionally, the region boasts a significant disease burden, with nearly 50 million Americans reported to be affected by autoimmune disorders. This substantial prevalence, coupled with substantial healthcare expenditures, has prompted the adoption of favorable government and industry-sponsored initiatives. The primary objectives of these initiatives are to mitigate healthcare costs by promoting early disease detection and enhancing public awareness among patients. Moreover, The U.S. autoimmune disease diagnostics industry is anticipated to experience a substantial influence on the market because of its high prevalence of these conditions. Although autoimmune diseases are rare, the National Institutes of Health (NIH) estimates that approximately 5% to 8% of the U.S. population is affected by these diseases. This expanding patient pool further strengthens the market prospects.

Recent Developments

• In February 2025, The Benaroya Research Institute is starting a new way to find autoimmune diseases early. They are adding a special blood test, called an autoantibody test, to regular checkups at the doctor’s office. This test can help spot diseases like type 1 diabetes and rheumatoid arthritis before any symptoms appear. Finding these diseases early can help doctors treat them sooner and possibly stop serious problems. Right now, pilot testing is underway.
• In January 2025, RheumaGen, a biotechnology company based in Aurora, Colorado, secured $15 million in Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The funds will support Phase I trials of RG0401, a gene-editing therapy targeting treatment-resistant rheumatoid arthritis by modifying HLA genes to prevent autoimmune responses. The company aims to develop one-time, curative treatments for autoimmune diseases, including multiple sclerosis and type 1 diabetes.
• In June 2023, AstraZeneca entered into an agreement with Quell Therapeutics to develop, manufacture, and commercialize engineered T-regulatory cell therapies for autoimmune diseases. The collaboration focuses on Type 1 Diabetes and Inflammatory Bowel Disease using Quell's proprietary multi-modular T-regulatory cell engineering. 
• In August of 2022, Beutner Laboratories, known as KSL Beutner Laboratories (Beutner), introduced a blood test designed to identify an antigen associated with the autoimmune blistering condition known as mucous membrane pemphigoid (MMP). This disease frequently leads to painful lesions occurring in the oral cavity.
• Meanwhile, in May 2022, Thermofisher launched the innovative Phadia 2500+ instrument series for autoimmune testing within the United States. This platform is known for its exceptional and dependable high throughput capabilities, serving both allergy diagnostics and autoimmune testing with unmatched reliability.

Key Market Players

• Abbott Laboratories
• Siemens Healthineers AG
• Roche Diagnostics Corp
• Beckman Coulter Inc
• SQI Diagnostics Inc
• EUROIMMUN Medizinische Labordiagnostika AG
• Aesku Diagnostics GmbH & Co KG
• INOVA Diagnostics Inc
• Crescendo Bioscience LLC
• bioMerieux SA

Report Scope:

In this report, the Global Autoimmune Disease Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Autoimmune Disease Diagnostics Market, By Component:

o   Instruments

o   Reagents

o   Consumables

• Autoimmune Disease Diagnostics Market, By Test Type:

o   Routine Laboratory Tests

o   Inflammatory Markers

o   Antibodies & Immunologic Tests

o   Others

• Autoimmune Disease Diagnostics Market, By Disease Type:

o   Systemic Autoimmune Disease Diagnostics

§  Rheumatoid Arthritis

§  Ankylosing Spondylitis

§  Systemic Lupus Erythematosus

§  Others

o   Localized Autoimmune Disease Diagnostics

§  Multiple Sclerosis

§  Type 1 Diabetes

§  Hashimoto’s Thyroiditis

§  Others

• Autoimmune Disease Diagnostics Market, By End User:

o   Hospitals & Clinics

o   Diagnostic Centers

o   Others

• Autoimmune Disease Diagnostics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoimmune Disease Diagnostics Market.

Available Customizations:

Global Autoimmune Disease Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Autoimmune Disease Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]